"New research on phrenic nerve stimulation for HF patients with CSA"

Sharing our new publication, led by Ali Azarbarzin, identifying which patients with heart failure (HF) benefit most from treatment of their central sleep apnea using phrenic nerve stimulation. The study showed that people whose central sleep apnea (CSA) caused large surges in heart rate at baseline, later went on to have an 8-percentage point greater improvement in left ventricular ejection fraction with CSA treatment than those with small heart rate surges, over the 6-month trial. Article: https://lnkd.in/efFUv5Nj Longer-term observational data also showed consistent findings: over 12 months, those with larger CSA-induced heart rate surges experienced early and sustained heart function benefit long term that was not seen with lower heart rate surge patients. The work promises to enable future clinical prediction: i.e. selected patients with HF and CSA treated specifically to improve cardiac outcomes. Also, CSA — like OSA — now appears uniquely problematic when it provokes heart rate surges, but may not be harmful to the heart otherwise. OSA link: https://lnkd.in/eVmWubAg Thanks to our colleagues Robin Germany and Scott McKane at Zoll Respicardia for the excellent data and fruitful collaboration.

🚦 Why is NESA XSignal different from home-use vagus nerve devices? We’re often asked how NESA XSignal compares to devices like NeuroSym that work directly on the vagus nerve. 👉 Stimulating the vagus nerve can be very useful, it’s like fixing one set of traffic lights that are stuck on red. But the autonomic nervous system (ANS) is far more complex. It’s a global network of nerves regulating sleep, recovery, cardiovascular health, stress, digestion and more. If the vagus is one junction, the ANS is the whole traffic system. When the entire network is jammed and congested, clearing just one junction won’t restore full flow. That’s where NESA XSignal is different. Delivered in a professional clinical setting, it works across multiple nerve pathways in the hands and feet, not just the vagus to rebalance the ANS centrally, locally, and metamerically. The result? A more complete restoration of balance for patients seeking improvements in sleep, recovery, performance and resilience. 🧠 The ANS is complex. Your therapy should be too. 👉 Learn more: nesaclinics.co.uk Jenny Torney NESA WORLD Jonny Campbell

⏳ Deadline Extended! SLEEP Advances is inviting submissions for a special collection on Consumer Sleep Technology (CST). This issue will spotlight innovative insights and applications of CST in sleep medicine. We welcome: 📊 Observational studies 🧪 Interventional clinical trials 📑 Case reports, reviews, & meta-analyses 💭 Opinion papers 📅 New deadline: September 30 🔗 Learn more: https://lnkd.in/gnRdcP_j

NEW ARTICLE: 💔 Will the Use of CPAP Reduce Heart Disease? ❤️ A patient with untreated obstructive sleep apnea has about two to three times greater risk of heart disease. i Of course, when treated, the prevalence of heart disease should logically decrease. BUT – this may not be the case. “CPAP machines are extremely effective in treating obstructive sleep apnea and are great for improving sleep and reducing daytime fatigue, but we haven’t seen a reduction in heart disease that we expected, and we haven’t understood why,” says Sanja Jelic, MD, a critical care medicine specialist and sleep researcher at Columbia University Vagelos College of Physicians and Surgeons, in a release. READ: https://lnkd.in/eZ9cAgB6

Everyone has trouble sleeping once in awhile, but did you realize that creatine can help you get through a sleepless night and be at your peak performance for that critical meeting in the morning? The findings in this double blind clinical study were compelling: creatine stabilized critical brain energy markers—such as phosphocreatine (PCr)/inorganic phosphate (Pi), ATP levels, total creatine-to-total NAA ratios, and pH balance—and improved cognitive performance and processing speed relative to placebo. These effects became noticeable within 3 hours, peaked around 4 hours, and endured for up to 9 hours, suggesting that a single high dose can partially reverse the metabolic and cognitive impairments induced by sleep loss.

“Projections indicate that obstructive sleep apnoea will affect 76·6 million adults aged 30–69 years across the USA in 2050, with a disproportionate growth among females compared with males. These findings highlight the urgent need for targeted public health strategies and revised access to diagnosis and follow-up pathways to address the growing prevalence of obstructive sleep apnoea, particularly among females.” #osa #patientawareness #hughlyprevalent #femalerisk #snoring #daytimesleepiness #askyourdoctor #morningleaves

Sleep health is whole-body health. 💤 I recently reviewed the Cleveland Clinic Journal of Medicine’s article, “Obstructive Sleep Apnea Basics” by Dr. Jessica Vensel Rundo. It reinforced how OSA remains highly underdiagnosed, despite being linked to serious comorbidities such as hypertension, diabetes, and cardiovascular disease. The use of screening tools (STOP-BANG, Epworth Sleepiness Scale) and polysomnography as the gold standard are critical in improving diagnosis. Next week, I’ll be attending the Las Vegas Institute’s “The Physiologic Approach to Treating OSA” course to further expand my knowledge and clinical skills. The course will cover: 1. Dental sleep medicine and the dentist’s role in OSA care 2. Identifying and reviewing the medical issues of OSA and SDB 3. Airway anatomy, clinical forms, and screening tools 4. Polysomnography, WatchPAT, and CBCT imaging in diagnosis 5. Snoring, mouth breathing, UARS, and pediatric OSA 6. Integration of sleep appliances into practice, financial considerations, and device delivery I’m excited to deepen my understanding and bring these insights back into clinical practice to better serve patients. #SleepApnea #Dentistry #OSA #ContinuingEducation #LVI

The newest edition of the Canadian Journal of Respiratory, Critical Care and Sleep Medicine is now live! Discover the latest findings, including: the feasibility of an automated quality control algorithm for spirometry, pulmonary CT and MRI indicators of asthma remission, and the beneficial cycle of computed tomography measurements in individuals with COPD, and much more! 📖

Risk for retinal vein occlusion (RVO) is higher among patients with obstructive sleep apnea (OSA), according to results of a retrospective cohort study published in Eye. Read more: https://bit.ly/3HE0JG7 #Ophthalmology #RetinalVeinOcclusion #RVO #ObstructiveSleepApnea #OSA #EyeCare #EyeHealth #Ophthalmologist #EyeDoctor

New work in press from our team led by Daniel Vena and Sara Op de Beeck showing that hypoglossal nerve stimulation—which advances the tongue forward to treat obstructive sleep apnea—works best in patients without lateral i.e. "side-to-side" upper airway collapse. This is seen whether measured using a camera (endoscopy) under sedation in the operating room, or our non-invasive method to estimate lateral collapse from airflow shape in a home sleep test. Article: https://lnkd.in/eR8d4WTx The non-invasive method worked just as well as endoscopy for outcome prediction! This represents the first validated treatment prediction study in our field. A culimination of a decade of work that started with Andrew Wellman, MD, PhD's idea to predict site of collapse from airflow. Special kudos to our ENT collaborator Phillip Huyett, and our colleagues from Antwerp. More to follow from the Aggregated Data for Validating Advanced Non-invasive Clinical Endotypes (ADVANCE) consortium.